TAKEDA-PHARMACEUTICAL
3.6.2019 03:02:05 CEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK ) today became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion over five years, builds on Takeda's previous contribution to the Global Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190602005021/en/
Takeda, a leading global pharmaceutical company headquartered in Japan, intends to support the improvement of maternal and child health by integrating quality HIV, tuberculosis and malaria services in antenatal and postnatal care in several countries in Africa.
“We are very pleased to renew our partnership with Takeda and strengthen our collaboration in fighting HIV, TB and malaria,” said Peter Sands, Executive Director of the Global Fund. “I hope Takeda’s vote of confidence in the work we do will encourage other corporations in Asia and beyond to step up the fight to end the epidemics.”
Takeda’s first pledge of JP ¥ 1 billion over ten years was invested in strengthening the capacity of health care workers in Africa. It helped boost malaria prevention efforts in Tanzania with the distribution of mosquito nets; accelerated access to TB treatment in Kenya; and expanded HIV services and increased awareness of the virus in Nigeria.
“We are deeply inspired by the Takeda Initiative’s impact on strengthening healthcare workforce capacity in Kenya, Nigeria, and Tanzania to prevent and address the world’s three biggest infectious disease killers,” said Christophe Weber, President & CEO, Takeda Pharmaceutical Company. “Our commitment to Better Health and a Brighter Future extends beyond our work at the cutting edge of innovation to bold, long-term investments in disease prevention, capacity building, and access to healthcare in partnership with the global community. Supporting the Global Fund over the past 10 years has yielded results that are very important to us, and that is why we are proud to continue to partner with the Global Fund on the Takeda Initiative 2.”
The Global Fund has demonstrated extraordinary impact as a public-private partnership, saving 27 million lives since 2002. The number of people dying from AIDS, TB and malaria in countries where the Global Fund invests has been reduced by one-third.
France will convene the Global Fund’s Sixth Replenishment pledging conference on October 10, 2019 in Lyon, France. The Global Fund seeks to raise at least US$14 billion – US$1 billion from the private sector – for the next three years. The funds will help save 16 million lives, cut the mortality rate from HIV, TB and malaria in half, and build stronger health systems by 2023.
The renewal of the partnership was facilitated by the Friends of the Global Fund, Japan, operated by the Japan Center for International Exchange. Akio Okawara, President & CEO of JCIE, added: “Takeda’s continued commitment to support the global fight against the three diseases provides an exemplary model of private sector engagement and adds momentum to Japan’s public-private partnership efforts in promoting universal health coverage and achieving the Sustainable Development Goals.”
About the Global Fund
The Global Fund is a 21st-century
partnership designed to accelerate the end of AIDS, tuberculosis and
malaria as epidemics. As a partnership between governments, civil
society, the private sector and people affected by the diseases, the
Global Fund mobilizes and invests nearly US$4 billion a year to support
programs run by local experts in more than 100 countries. By challenging
barriers and embracing innovative approaches, we are working together to
better serve people affected by the diseases.
For more information,
visit www.theglobalfund.org
About Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited (TSE:4502/NYSE:TAK
)
is a global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed to bringing Better Health and a
Brighter Future to patients by translating science into
highly-innovative medicines. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and
Neuroscience. We also make targeted R&D investments in Plasma-Derived
Therapies and Vaccines. We are focusing on developing highly innovative
medicines that contribute to making a difference in people's lives by
advancing the frontier of new treatment options and leveraging our
enhanced collaborative R&D engine and capabilities to create a robust,
modality-diverse pipeline. Our employees are committed to improving
quality of life for patients and to working with our partners in health
care in approximately 80 countries and regions.
For more
information, visit www.takeda.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190602005021/en/
Contact:
Media Contacts The Global Fund Dominique De Santis Email: dominique.desantis@theglobalfund.org Tel: +41 78 911 5327
Takeda Pharmaceutical Company Kazumi Kobayashi Email: Kazumi.kobayashi@takeda.com Tel : +81-3-3278-2095
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom